Search Results

5 results

  1. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 04

    Reduction of harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    D’RUIZ C.D.(1); O’CONNELL G.(2); GRAFF D.W.(3)
    (1) Scientific Affairs Consultant, Fontem Ventures, B.V., Greensboro, NC, U.S.A.; (2) Fontem Ventures, B.V., Scientific and Regulatory Affairs, Amsterdam, The Netherlands; (3) Celerion, Lincoln, NE, U.S.A.
    Changes in fifteen urine, blood, and exhaled breath biomarkers of exposure (BoE) to harmful and potentially harmful constituents (HPHCs), representing major classes of compounds reported by the FDA to be significant contributors to smoking-associated...
  2. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 23

    Pharmacokinetics of nicotine following single controlled use of a new type of tobacco: heated tobacco product

    GILES L.(1); YUKI D.(2); SHERWOOD N.(3); GRAFF D.W.(4); NEWLAND K.(4)
    (1) JT International SA, Ballymena, Co. Antrim, U.K.; (2) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (3) Neil Sherwood Consulting, Commugny, Switzerland; (4) Celerion, Lincoln, NE, U.S.A.
    Nicotine is one of the most characteristic compounds contained in any type of tobacco product including cigarettes. Previous studies have reported that different types of tobacco products display differences in nicotine pharmacokinetics. NHTP is a...
  3. TSRC, Tob. Sci. Res. Conf., 2016, 70, abstr. 23

    Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    O’CONNELL G.(1); GRAFF D.W.(2); D’RUIZ C.(3)
    (1) Fontem Ventures B.V, Amsterdam, The Netherlands; (2) Celerion Inc, Lincoln, NE, USA; (3) Fontem Ventures B.V Greensboro, NC, USA
    Changes in fifteen urine, blood and exhaled breath BoEs of HPHCs representing classes of compounds reported by FDA to be significant contributors to smoking-associated disease risks were measured in 105 clinical-confined subjects following...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2013, Seville, ST 22

    The statistical benefit of performing GLP bioanalysis using assays that have reduced variability

    FARMEN R.H.; NEWLAND K.E.; GRAFF D.W.; COMBS M.L.
    Celerion, Lincoln, NE, U.S.A.; Celerion, Zürich, Switzerland
    Since the tobacco industry is moving into the area of regulated bioanalysis, we have noted that there is confusion surrounding the type of regulatory standards required for analytical methods to be used for testing tobacco constituents and biomarkers...